LivaNova (NASDAQ:LIVN) Stock Price Expected to Rise, Robert W. Baird Analyst Says

LivaNova (NASDAQ:LIVN) had its price target upped by research analysts at Robert W. Baird from $95.00 to $111.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird‘s price target would suggest a potential upside of 17.85% from the stock’s previous close.

Several other research firms have also recently issued reports on LIVN. Jefferies Financial Group reiterated a “buy” rating on shares of LivaNova in a report on Wednesday. Weiss Ratings raised LivaNova from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, October 27th. Mizuho set a $115.00 price objective on LivaNova in a research note on Wednesday. Stifel Nicolaus set a $85.00 target price on LivaNova in a report on Wednesday, August 5th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $90.00 price target (up from $87.00) on shares of LivaNova in a research report on Wednesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $99.56.

LivaNova Price Performance

LIVN opened at $94.19 on Thursday. The company has a 50 day moving average of $78.85 and a two-hundred day moving average of $73.25. The company has a market cap of $5.19 billion, a P/E ratio of 22.26 and a beta of 0.91. LivaNova has a 52-week low of $48.82 and a 52-week high of $99.38. The company has a quick ratio of 1.21, a current ratio of 1.45 and a debt-to-equity ratio of 0.22.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.17. The company had revenue of $393.15 million for the quarter, compared to the consensus estimate of $381.13 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%. LivaNova’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.11 EPS. On average, analysts expect that LivaNova will post 3.78 earnings per share for the current year.

Insider Activity

In other news, Director Francesco Bianchi sold 3,500 shares of the stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $78.01, for a total transaction of $273,035.00. Following the completion of the sale, the director owned 4,434 shares of the company’s stock, valued at $345,896.34. This represents a 44.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brooke Story sold 2,300 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the completion of the sale, the director owned 7,488 shares in the company, valued at approximately $609,672.96. This trade represents a 23.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 7,450 shares of company stock valued at $591,839 over the last 90 days. Corporate insiders own 0.35% of the company’s stock.

Institutional Trading of LivaNova

Several large investors have recently added to or reduced their stakes in LIVN. AlphaCore Capital LLC bought a new position in shares of LivaNova during the third quarter valued at $308,000. Hohimer Wealth Management LLC grew its holdings in LivaNova by 5.4% during the 3rd quarter. Hohimer Wealth Management LLC now owns 4,277 shares of the company’s stock valued at $327,000 after buying an additional 219 shares in the last quarter. Alamar Capital Management LLC purchased a new stake in LivaNova in the 3rd quarter worth $1,814,000. Covestor Ltd lifted its position in shares of LivaNova by 135.1% in the third quarter. Covestor Ltd now owns 1,300 shares of the company’s stock worth $99,000 after buying an additional 747 shares in the last quarter. Finally, Vise Technologies Inc. increased its stake in LivaNova by 40.3% in the 3rd quarter. Vise Technologies Inc. now owns 3,915 shares of the company’s stock worth $299,000 after acquiring an additional 1,124 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Key LivaNova News

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: LivaNova reported Q3 earnings of $1.23 per share, above analyst estimates of $1.03–$1.06 and up from $1.11 a year earlier. Revenue rose 9.9% year over year to $393.2 million, also beating estimates. LivaNova Q3 earnings report
• Positive Sentiment: The company raised its 2026 adjusted EPS guidance to $4.40–$4.50 and forecast revenue growth of 9%–10%, signaling confidence in continued growth. 2026 outlook
• Positive Sentiment: Needham raised its price target to $112 from $93 and maintained a Buy rating, adding to the bullish analyst reaction. Needham rating update
• Neutral Sentiment: LivaNova is exploring entry into neuromodulation for obstructive sleep apnea, which could offer a longer-term growth opportunity, though the report describes an area the company is eyeing rather than a near-term revenue driver. OSA neuromodulation plans

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.